Compugen Ltd. - Ordinary Shares (CGEN) News
Filter CGEN News Items
CGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CGEN News Highlights
- CGEN's 30 day story count now stands at 6.
- Over the past 9 days, the trend for CGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CGEN are CERT, CRC and GENE.
Latest CGEN News From Around the Web
Below are the latest news stories about COMPUGEN LTD that investors may wish to consider to help them evaluate CGEN as an investment opportunity.
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) annual meeting on April 14-19, 2023, in Orlando, Florida. |
Is Certara (CERT) Outperforming Other Medical Stocks This Year?Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year. |
Compugen (NASDAQ:CGEN investor three-year losses grow to 90% as the stock sheds US$11m this past weekIt's not possible to invest over long periods without making some bad investments. But really bad investments should be... |
Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call TranscriptCompugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Fourth Quarter and Full Year 2022 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investors section […] |
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare ConferenceCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference (virtual), on Wednesday, March 15, 2023 at 10:00 AM ET. |
Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept StudyCompugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient has been dosed in the triple combination proof-of-concept study evaluating COM701, Compugen's potential first-in-class anti-PVRIG antibody, in combination with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC). |
Why Compugen Shares Are Up TodayShares of Compugen (NASDAQ: CGEN) rose more than 10% in early trading Tuesday, a day after the clinical-stage cancer immunotherapy company reported its fourth-quarter and full-year results. The biotech stock has been climbing since it announced on Feb. 14 that AstraZeneca was planning to begin its Phase 3 study with rilvegostomiq, derived from Compugen's PD-1/TIGIT bi-specific therapy, COM902, as a therapy in several indications and combinations. Then after the market closed Monday, Compugen delivered more good news in its earnings report. |
Compugen Reports Fourth Quarter and Full Year 2022 ResultsCompugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2022 and provided an update on its main highlights from 2022 and future plans. |
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported today that rilvegostomig, AstraZeneca's bi-specific antibody derived from Compugen's COM902, is expected to progress into Phase 3 this year. AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody and is also developing an expanded Phase 2 program. |
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. |